Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

E1700000

Estrone

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,3,5(10)-estratriène-3-ol-17-one, Folliculine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H22O2
Numéro CAS:
53-16-7
Poids moléculaire :
270.37
Numéro Beilstein :
1915077
Numéro MDL:
MFCD00003620
Code UNSPSC :
41116107
ID de substance PubChem :
329799017
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Agence

EP Reference Standard

Famille d'API

estrone

Fabricant/nom de marque

EDQM

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Pf

258-260 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O

InChI

1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1

Clé InChI

DNXHEGUUPJUMQT-CBZIJGRNSA-N

Informations sur le gène

human ... ESR1(2099)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Estrone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H351,H360FD,H362

Classification des risques

Carc. 2 - Lact. - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

β-Estradiol analytical standard

Sigma-Aldrich

E1132

β-Estradiol

β-Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1353

β-Estradiol

β-Estradiol meets USP testing specifications

Sigma-Aldrich

E1024

β-Estradiol

Emma M Ferguson et al.
Water research, 47(4), 1604-1615 (2013-01-12)
Estuaries are often the final repositories for aquatic pollutants but how estuarine hydrology influences the availability of marine- and freshwater-derived pollutants is not well understood, particularly for micro-pollutants such as endocrine disrupting chemicals. To address this knowledge gap, this study
Juilee Rege et al.
The Journal of clinical endocrinology and metabolism, 98(3), 1182-1188 (2013-02-07)
A broad analysis of adrenal gland-derived 19-carbon (C19) steroids has not been reported. This is the first study that uses liquid chromatography-tandem mass spectrometry to quantify 9 C19 steroids (androgens and their precursors), estrone, and estradiol in the adrenal vein
B Zumoff et al.
Arteriosclerosis (Dallas, Tex.), 2(1), 58-67 (1982-01-01)
Plasma concentrations and urinary excretions of various hormones and hormone metabolites were measured in four groups. Group 1 was composed of 13 men with prior myocardial infarction; Group 2 contained 35 clinically normal men; Group 3 consisted of 44 men
Shanshan Zhao et al.
Breast cancer research : BCR, 16(2), R30-R30 (2014-03-29)
Paradoxically, a breast cancer risk reduction with conjugated equine estrogens (CEE) and a risk elevation with CEE plus medroxyprogesterone acetate (CEE + MPA) were observed in the Women's Health Initiative (WHI) randomized controlled trials. The effects of hormone therapy on serum sex
E Van Caenegem et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 26(1), 35-47 (2014-11-08)
Although trans women before the start of hormonal therapy have a less bone and muscle mass compared with control men, their bone mass and geometry are preserved during the first 2 years of hormonal therapy, despite of substantial muscle loss, illustrating
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique